Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
Stoke Therapeutics has completed enrollment of 162 patients in the Phase 3 EMPEROR study of zorevunersen for Dravet syndrome, hitting this milestone in just 10 months. The company plans to initiate a rolling U.S. NDA submission in the first quarter of 2027, with a data readout anticipated in the third quarter of 2027 to complete the submission in the second half of the year.
Key figures
- Drug Name
- Zorevunersen
- Phase Of Trial
- Phase 3
- Patients enrolled
- 162
- Primary endpoint week
- 28
- Enrollment duration months
- 10
- Total treatment period weeks
- 52
- Additional patients enrolling europe
- 30
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.